Zobrazeno 1 - 10 of 24 pro vyhledávání: '"J, Boukovinas"'
3
A Multicenter Phase II Study of the Combination of Irinotecan and Gemcitabine in Previously Treated Patients with Small-Cell Lung Cancer
Autor: Sophia Agelaki, Athanasios Athanasiadis, Charalambos Kouroussis, Maltezakis G, Charalambos Christophylakis, G. Milaki, Varthalitis J, N. Vardakis, Georgoulias, Kostas N. Syrigos, Georgia Pavlakou, J. Boukovinas
Publikováno v: Oncology. 66:192-196
Objective: To evaluate efficacy and toxicity of the combination of irinotecan and gemcitabine in pretreated patients having small-cell lung cancer. Patients andMethods: Thirty-one patients (median age 60 years, performance status 0–1 in 87% and 2 i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bba6d30a2e123588e958c410cf1a9eb
https://doi.org/10.1159/000077994
Zobrazit plný text záznamu
4
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)
Autor: P. Kosmidis, C. Bakogiannis, Sofia Lambaki, J. Boukovinas, Anastasia G Eleftheraki, Kostas N. Syrigos, George Fountzilas, Meletios A. Dimopoulos, D.G. Pectasides, N. Katirtzoglou, D.V. Skarlos, Dimitris Bafaloukos, Georgios Pentheroudakis, H. P. Kalofonos, Epaminontas Samantas
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 22(4)
BACKGROUND: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1666c49f61b226f0892b48620b169b18
https://pubmed.ncbi.nlm.nih.gov/20880999
Zobrazit plný text záznamu
5
Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study
Autor: P, Kosmidis, G, Fountzilas, S, Baka, E, Samantas, A M, Dimopoulos, H, Gogas, D, Skarlos, P, Papacostas, J, Boukovinas, Ch, Bakogiannis, P, Pantelakos, H, Athanasiou, D, Misailidou, P, Tsekeris, N, Pavlidis
Publikováno v: Anticancer research. 27(6C)
Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable nonsmall cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy followin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b50092d0da81bcd5c1d184ded356aebb
https://pubmed.ncbi.nlm.nih.gov/18214050
Zobrazit plný text záznamu
9
Docetaxel, cisplatin and gemcitabine as first line for patients with advanced/metastatic head and neck cancer
Autor: C. H. Christophillakis, Charalambos Kouroussis, L. Helis, Aristidis Polyzos, A. Potamianou, Kostas N. Syrigos, J. Boukovinas, Sophia Agelaki, E. Tselepatiotis, L. Vamvakas, Nikos Androulakis
Publikováno v: Journal of Clinical Oncology. 23:5586-5586
5586 Background: Docetaxel, cisplatin and gemcitabine are active drugs in head and neck cancer. A phase II study was conducted to evaluate the activity of their combination in patients with relapse...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20983a204250d47194dfa534bbae3265
https://doi.org/10.1200/jco.2005.23.16_suppl.5586
Zobrazit plný text záznamu
10
A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER
Autor: V. Georgoulias, D. Mavroudis, N. Malamos, A. Kotsakis, Aristidis Polyzos, Athanasios G. Pallis, J. Boukovinas, Charalambos Kouroussis, E. Tsiakopoulos, G. Milaki
Publikováno v: Journal of Clinical Oncology. 22:728-728
728 Background: To evaluate the activity and toxicity of the docetaxel-gemcitabine-trastuzumab combination in the first-line treatment of ABC overexpressing HER-2. Methods: Previously untreated patients with 2+ or 3+ HER-2 overexpressing ABC who had
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::faee794b86b8bc83df3eca08a70aa796
https://doi.org/10.1200/jco.2004.22.90140.728
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje